Hartmut Goldschmidt
University Hospital Heidelberg · GMMG study group · Med. Klinik V, University Hospital Heidelberg
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hartmut Goldschmidt as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:08 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07111884 · GMMG Multiple Myeloma RegistryProf. Dr. Hartmut Goldschmidt · recruiting · Multiple Myeloma · principal investigator
- Ph3NCT06216158 · Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple MyelomaUniversity of Heidelberg Medical Center · active not recruiting · Multiple Myeloma · principal investigator
- Ph3NCT05804032 · Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple MyelomaUniversity of Heidelberg Medical Center · completed · Multiple Myeloma · principal investigator
- Ph3NCT03617731 · Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)University of Heidelberg Medical Center · active not recruiting · Multiple Myeloma · principal investigator
- Ph3NCT02495922 · A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed MyelomaUniversity of Heidelberg Medical Center · completed · Multiple Myeloma · principal investigator
- Ph2NCT01105403 · Exploratory Study on POL6326 in Stem Cell MobilizationPolyphor Ltd. · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:08 UTC. The ranking covers the 200 most relevant of 165 PubMed records, and a shared surname and initials can bring in a namesake. All 165 on PubMed
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.N Engl J Med · 20212,208 citationsRCR 120.1
- Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.N Engl J Med · 20052,076 citationsRCR 41.6
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.N Engl J Med · 20161,208 citationsRCR 41.0
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.N Engl J Med · 2019853 citationsRCR 33.9
- 756 citationsRCR 25.0
- 670 citationsRCR 18.7
- Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.J Clin Oncol · 2012664 citationsRCR 18.1
- 414 citationsRCR 8.6
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.Lancet Oncol · 2017337 citationsRCR 11.0
- 337 citationsRCR 19.3